An observational trial investigating the efficacy and safety of dabigatran, rivaroxaban, and warfarin for stroke prevention in patients with atrial fibrillation.
Latest Information Update: 03 Dec 2016
Price :
$35 *
At a glance
- Drugs Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Warfarin (Primary)
- Indications Stroke
- Focus Therapeutic Use
- 03 Dec 2016 New trial record
- 28 Nov 2016 Results published in the Clinical Cardiology